Amgen (AMGN) Liabilities and Shareholders Equity (2009 - 2026)

Amgen (AMGN) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $92.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 3.51% year-over-year to $92.5 billion; the TTM figure through Mar 2026 stood at $361.1 billion (down 0.51% YoY), while the FY2025 annual figure was $90.6 billion, down 1.36% from the prior year.
• Liabilities and Shareholders Equity came in at $92.5 billion for Q1 2026 at Amgen, up from $90.6 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $97.2 billion in Q4 2023, with the low at $59.2 billion in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $84.2 billion, with a median of $90.3 billion recorded in 2023.
• Across the five-year window, Liabilities and Shareholders Equity soared 52.24% in 2023 and slipped 5.47% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $65.1 billion in 2022, then surged by 49.19% to $97.2 billion in 2023, then decreased by 5.47% to $91.8 billion in 2024, then slipped by 1.36% to $90.6 billion in 2025, then advanced by 2.12% to $92.5 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $92.5 billion, $90.6 billion, and $90.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.